Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above

NCT04838444 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT04838444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 2, 2021
Completion date
May 31, 2031
Enrollment
363 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection